Page 10 - Private Equity Exits via Initial Public Offerings 2016

Date Company Sector Private Market IPO Sell down Price Aggregate Banks Under- Commission /fee Total Private equity Private equity
equity cap size as a change sponsor written structure estimated sponsor sponsor lock-up
sponsor(s) at IPO (£m) 1 proportion since retained expenses relationship + orderly market
3
(£m) of IPO (%) 2 IPO (%) stake at (including agreement periods (months
4
IPO (%) commissions (key terms) from IPO)
(£m)
6 Oxford Pharma, Vulpes Life 136.0 20.0 7.8 - 4.0 23.5 Stifel, No 4% in respect of 1.7 N/A 6+6
Dec BioDy- Biotech Sciences Sanlam placees introduced
2016 namics and Fund, Odey Securities, by Stifel and 0.5%
plc Healthcare Funds Wentworth in respect of
placees not
introduced by
Stifel payable to
Stifel plus a fee of
£200,000
4% payable to
Sanlam Securitas in
respect of placees
introduced by them
Warrant issued
to Wentworth in
respect of 2% of
the enlarged share
capital
9 Creo Health Finance 61.3 20.0 No sell 39.5 34.3 Cenkos No 5% in respect of 2.1 N/A 12+12
Dec Medical Care Wales, down Securities placees introduced
2016 Group plc Equipment Angel by Cenkos and
& Services CoFund, 2.% in respect of
Hoya placees introduced
Corporation by the company
plus corporate
finance fee of
£315,000, all of
which satisfied
via the issue of
shares to Cenkos
Securities

Private equity exits via Initial Public Offerings (IPOs)